Các dấu ấn sinh học cho kết quả sau ghép tế bào gốc huyết học

Zeiser, 2017, Acute graft-versus-host disease–biologic process, prevention, and therapy, N Engl J Med, 377, 2167, 10.1056/NEJMra1609337 Zeiser, 2017, Pathophysiology of chronic graft-versus-host disease and therapeutic targets, N Engl J Med, 377, 2565, 10.1056/NEJMra1703472 Wingard, 2011, Long-term survival and late deaths after allogeneic hematopoietic cell transplantation, J Clin Oncol, 29, 2230, 10.1200/JCO.2010.33.7212 Paczesny, 2015, National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III, The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant, 21, 780 Petersdorf, 2017, Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation, F1000 Res, 6, 617, 10.12688/f1000research.10990.1 Martin, 2017, Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease, Blood, 129, 791, 10.1182/blood-2016-09-737700 Sucheston-Campbell, 2016, Functional single nucleotide polymorphisms (SNPs) in the major histocompatibility complex (MHC) class II region are associated with overall survival (OS) after HLA matched unrelated donor BMT: results from the Discovery-BMT Study, Biol Blood Marrow Transplant, 22, S72, 10.1016/j.bbmt.2015.11.365 Martin, 2016, Replication of associations between genetic polymorphisms and chronic graft-versus-host disease, Blood, 128, 2450, 10.1182/blood-2016-07-728063 Karaesmen, 2017, Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant, Blood, 130, 1585, 10.1182/blood-2017-05-784637 Sucheston-Campbell, Donor SNPs in IL1RL1, strongly correlated with serum sST2 concentration, significantly associate with risk of acute GvHD: implications for donor selection Chaussabel, 2015, A vision and a prescription for big data-enabled medicine, Nat Immunol, 16, 435, 10.1038/ni.3151 Nakaya, 2015, Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures, Immunity, 43, 1186, 10.1016/j.immuni.2015.11.012 Bontha, 2017, Systems biology in kidney transplantation: the application of multi-omics to a complex model, Am J Transplant, 17, 11, 10.1111/ajt.13881 Kurian, 2017, Orthogonal comparison of molecular signatures of kidney transplants with subclinical and clinical acute rejection: equivalent performance is agnostic to both technology and platform, Am J Transplant, 17, 2103, 10.1111/ajt.14224 Moss, 2016, Transplantation: utilizing the transcriptome to predict allograft fibrosis, Nat Rev Nephrol, 12, 652, 10.1038/nrneph.2016.134 Pidala, 2015, Tolerance associated gene expression following allogeneic hematopoietic cell transplantation, PLoS One, 10, e0117001, 10.1371/journal.pone.0117001 Pidala, 2016, A combined biomarker and clinical panel for chronic graft versus host disease diagnosis, J Pathol Clin Res, 3, 3, 10.1002/cjp2.58 Ranganathan, 2012, Regulation of acute graft-versus-host disease by microRNA-155, Blood, 119, 4786, 10.1182/blood-2011-10-387522 Leonhardt, 2013, Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100, Blood, 121, 3307, 10.1182/blood-2012-07-442665 Xiao, 2013, Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease, Blood, 122, 3365, 10.1182/blood-2013-06-510586 Stickel, 2017, MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation, Leukemia, 31, 2732, 10.1038/leu.2017.137 Chen, 2015, MicroRNA-155-deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation, Blood, 126, 103, 10.1182/blood-2014-12-617258 Sun, 2015, Mature T cell responses are controlled by microRNA-142, J Clin Invest, 125, 2825, 10.1172/JCI78753 Saha, 2016, Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality, J Clin Invest, 126, 2642, 10.1172/JCI85796 Gartlan, 2015, Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects, Blood, 126, 1609, 10.1182/blood-2015-01-622662 Furlan, 2016, Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells, Blood, 128, 2568, 10.1182/blood-2016-07-726547 Furlan, 2015, Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention, Sci Transl Med, 7, 315ra191, 10.1126/scitranslmed.aad3231 Tkachev, 2017, Combined OX40L and mTOR blockade controls effector T cell activation while preserving T reg reconstitution after transplant, Sci Transl Med, 9, 10.1126/scitranslmed.aan3085 Hakim, 2016, Upregulation of IFN-inducible and damage-response pathways in chronic graft-versus-host disease, J Immunol, 197, 3490, 10.4049/jimmunol.1601054 Zheng, 2017, Massively parallel digital transcriptional profiling of single cells, Nat Commun, 8, 14049, 10.1038/ncomms14049 Taur, 2014, The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation, Blood, 124, 1174, 10.1182/blood-2014-02-554725 Peled, 2017, Intestinal microbiota and relapse after hematopoietic-cell transplantation, J Clin Oncol, 35, 1650, 10.1200/JCO.2016.70.3348 Jenq, 2015, Intestinal blautia is associated with reduced death from graft-versus-host disease, Biol Blood Marrow Transplant, 21, 1373, 10.1016/j.bbmt.2015.04.016 Andermann, Microbiome-host interactions in hematopoietic stem cell transplant recipients [published online ahead of print 19 February 2018], Biol Blood Marrow Transplant Mann, 2003, Proteomic analysis of post-translational modifications, Nat Biotechnol, 21, 255, 10.1038/nbt0303-255 Altelaar, 2013, Next-generation proteomics: towards an integrative view of proteome dynamics, Nat Rev Genet, 14, 35, 10.1038/nrg3356 MacLean, 2006, General framework for developing and evaluating database scoring algorithms using the TANDEM search engine, Bioinformatics, 22, 2830, 10.1093/bioinformatics/btl379 Magenau, 2010, Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease, Biol Blood Marrow Transplant, 16, 907, 10.1016/j.bbmt.2010.02.026 Zorn, 2005, Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease, Blood, 106, 2903, 10.1182/blood-2005-03-1257 Matsuoka, 2010, Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation, J Clin Invest, 120, 1479, 10.1172/JCI41072 Koreth, 2011, Interleukin-2 and regulatory T cells in graft-versus-host disease, N Engl J Med, 365, 2055, 10.1056/NEJMoa1108188 Sarantopoulos, 2009, Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease, Blood, 113, 3865, 10.1182/blood-2008-09-177840 Flynn, 2015, Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease, Blood, 125, 4085, 10.1182/blood-2014-08-595470 Forcade, 2016, Circulating T follicular helper cells with increased function during chronic graft-versus-host disease, Blood, 127, 2489, 10.1182/blood-2015-12-688895 Kamihara, 2017, Low-dose interleukin-2 therapy activates circulating T follicular regulatory cells and suppresses circulating T follicular helper cells in patients with chronic Gvhd [abstract], Blood, 130, 74, 10.1182/blood.V130.Suppl_1.74.74 Mavers, 2017, Invariant natural killer T cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation, Front Immunol, 8, 900, 10.3389/fimmu.2017.00900 Li, 2016, Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease, JCI Insight, 1, 10.1172/jci.insight.86660 Forcade, 2017, An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition, JCI Insight, 2, 10.1172/jci.insight.92111 Stikvoort, 2017, Combining flow and mass cytometry in the search for biomarkers in chronic graft-versus-host disease, Front Immunol, 8, 717, 10.3389/fimmu.2017.00717 Mowat, 2004, Intestinal graft-vs.-host disease, Graft-vs-host disease, 279 Miklos, 2017, Ibrutinib for chronic graft-versus-host disease after failure of prior therapy, Blood, 130, 2243, 10.1182/blood-2017-07-793786 Barrett, 2017, Transplant biomarkers ready for the clinic?, Blood, 129, 137, 10.1182/blood-2016-11-751842 Vander Lugt, 2013, ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death, N Engl J Med, 369, 529, 10.1056/NEJMoa1213299 Abu Zaid, 2017, Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT, Blood, 129, 162, 10.1182/blood-2016-08-735324 Yu, 2016, Biomarker panel for chronic graft-versus-host disease, J Clin Oncol, 34, 2583, 10.1200/JCO.2015.65.9615 Hartwell, 2017, An early-biomarker algorithm predicts lethal graft-versus-host disease and survival, JCI Insight, 2, e89798, 10.1172/jci.insight.89798 von Elm, 2007, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Lancet, 370, 1453, 10.1016/S0140-6736(07)61602-X Bossuyt, 2003, The STARD initiative, Lancet, 361, 71, 10.1016/S0140-6736(03)12122-8 Gu, 2011, Estimating the diagnostic likelihood ratio of a continuous marker, Biostatistics, 12, 87, 10.1093/biostatistics/kxq045 Paczesny, 2009, A biomarker panel for acute graft-versus-host disease, Blood, 113, 273, 10.1182/blood-2008-07-167098 Ponce, 2015, High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation, Blood, 125, 199, 10.1182/blood-2014-06-584789 Kanakry, 2017, Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide, Haematologica, 102, 932, 10.3324/haematol.2016.152322 McDonald, 2015, Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment, Blood, 126, 113, 10.1182/blood-2015-03-636753 Levine, 2015, A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study, Lancet Haematol, 2, e21, 10.1016/S2352-3026(14)00035-0 Nelson, 2014, Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation, Biol Blood Marrow Transplant, 20, 1861, 10.1016/j.bbmt.2014.06.039 Kennedy, 2014, Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial, Lancet Oncol, 15, 1451, 10.1016/S1470-2045(14)71017-4 Paczesny, 2010, Elafin is a biomarker of graft-versus-host disease of the skin, Sci Transl Med, 2, 13ra2, 10.1126/scitranslmed.3000406 Brüggen, 2015, Epidermal elafin expression is an indicator of poor prognosis in cutaneous graft-versus-host disease, J Invest Dermatol, 135, 999, 10.1038/jid.2014.489 Ferrara, 2011, Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease, Blood, 118, 6702, 10.1182/blood-2011-08-375006 Levine, 2012, Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study, Blood, 119, 3854, 10.1182/blood-2012-01-403063 Harris, 2012, Plasma biomarkers of lower gastrointestinal and liver acute GVHD, Blood, 119, 2960, 10.1182/blood-2011-10-387357 Hansen, 2013, A novel soluble form of Tim-3 associated with severe graft-versus-host disease, Biol Blood Marrow Transplant, 19, 1323, 10.1016/j.bbmt.2013.06.011 Luft, 2007, Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease, Blood, 110, 4535, 10.1182/blood-2006-10-049817 Weissinger, 2007, Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, Blood, 109, 5511, 10.1182/blood-2007-01-069757 Weissinger, 2017, The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation, Leukemia, 31, 654, 10.1038/leu.2016.259 Weissinger, 2017, The multicentre, double-blinded, placebo-controlled clinical-trial (pre-GvHD) for prediction and pre-emptive treatment of acute GvHD [abstract], Blood, 130, 512 Weber, 2015, Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome, Blood, 126, 1723, 10.1182/blood-2015-04-638858 Rodriguez-Otero, 2012, Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease, Blood, 119, 5909, 10.1182/blood-2011-12-397968 Holtan, 2016, Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors, Blood, 128, 2350, 10.1182/blood-2015-09-669846 Ramadan, 2017, Specifically differentiated T cell subset promotes tumor immunity over fatal immunity, J Exp Med, 214, 3577, 10.1084/jem.20170041 Amin, Low amphiregulin expression in intestinal biopsies of patients with acute graft-versus-host disease, 10.1016/j.bbmt.2017.12.142 Sarantopoulos, 2015, Aberrant B-cell homeostasis in chronic GVHD, Blood, 125, 1703, 10.1182/blood-2014-12-567834 Saliba, 2017, B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality, Bone Marrow Transplant, 52, 1010, 10.1038/bmt.2017.73 Alho, 2016, Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD, Blood, 127, 646, 10.1182/blood-2015-10-672345 Liu, 2016, Proteomic characterization reveals that MMP-3 correlates with bronchiolitis obliterans syndrome following allogeneic hematopoietic cell and lung transplantation, Am J Transplant, 16, 2342, 10.1111/ajt.13750 Kariminia, 2016, Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells, Blood, 127, 3082, 10.1182/blood-2015-09-668251 Paczesny, 2016, CXCL10: most consistent cGVHD biomarker?, Blood, 127, 2950, 10.1182/blood-2016-04-709543 Inamoto, 2017, Association of plasma CD163 concentration with de novo-onset chronic graft-versus-host disease, Biol Blood Marrow Transplant, 23, 1250, 10.1016/j.bbmt.2017.04.019 Du, 2018, Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients, Blood, 131, 1743, 10.1182/blood-2017-08-800623 Akil, 2015, Biomarkers for diagnosis and prognosis of sinusoidal obstruction syndrome after hematopoietic cell transplantation, Biol Blood Marrow Transplant, 21, 1739, 10.1016/j.bbmt.2015.07.004 Rotz, 2017, ST2 and endothelial injury as a link between GVHD and microangiopathy, N Engl J Med, 376, 1189, 10.1056/NEJMc1700185 Rotz, 2017, In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy, Blood Adv, 1, 1632, 10.1182/bloodadvances.2017008250 Luft, 2017, EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis, Lancet Haematol, 4, e414, 10.1016/S2352-3026(17)30108-4 Seo, Diagnostic and prognostic plasma biomarkers for idiopathic pneumonia syndrome after hematopoietic cell transplantation [published online ahead of print 6 December 2017], Biol Blood Marrow Transplant Johnpulle, 2017, Metabolic complications precede alloreactivity and are characterized by changes in suppression of tumorigenicity 2 signaling, Biol Blood Marrow Transplant, 23, 529, 10.1016/j.bbmt.2016.12.627 Paczesny, 2013, Discovery and validation of graft-versus-host disease biomarkers, Blood, 121, 585, 10.1182/blood-2012-08-355990 Paczesny, 2017, Acute graft-versus-host disease prognosis: are biomarkers ready for preemptive clinical trials?, Clin Chem, 63, 1561, 10.1373/clinchem.2017.272872 McDonald, 2017, Predictive value of clinical findings and plasma biomarkers after fourteen days of prednisone treatment for acute graft-versus-host disease, Biol Blood Marrow Transplant, 23, 1257, 10.1016/j.bbmt.2017.04.029 Wolff, Biomarkers in chronic graft-versus-host disease: quo vadis? [published online ahead of print 24 January 2018], Bone Marrow Transplant Zhang, 2015, ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease, Sci Transl Med, 7, 308ra160, 10.1126/scitranslmed.aab0166 Reichenbach, 2015, The IL-33/ST2 axis augments effector T-cell responses during acute GVHD, Blood, 125, 3183, 10.1182/blood-2014-10-606830 Bruce, 2017, Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease, J Clin Invest, 127, 1813, 10.1172/JCI91816 Sarantopoulos, 2007, High levels of B-cell activating factor in patients with active chronic graft-versus-host disease, Clin Cancer Res, 13, 6107, 10.1158/1078-0432.CCR-07-1290 Fujii, 2008, Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children’s Oncology Group, Blood, 111, 3276, 10.1182/blood-2007-08-106286 Kitko, 2014, Plasma CXCL9 elevations correlate with chronic GVHD diagnosis, Blood, 123, 786, 10.1182/blood-2013-08-520072